Wells Fargo & Company Actinium Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 19,994 shares of ATNM stock, worth $22,993. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,994
Previous 14,559
37.33%
Holding current value
$22,993
Previous $27,000
7.41%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ATNM
# of Institutions
70Shares Held
8.26MCall Options Held
79.6KPut Options Held
21.7K-
Black Rock Inc. New York, NY1.88MShares$2.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.62MShares$1.86 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA688KShares$791,0300.0% of portfolio
-
State Street Corp Boston, MA621KShares$714,2360.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$574,1490.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $29M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...